Ultrasound-mediated therapies using receptor-targeted nanodroplets

P. Schumann, R. Labell, K. Penrose, A. Kerschen, Evan C Unger, Terry O Matsunaga, R. Zutshi

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Angiogenic vessels at tumor sites are leaky and allow particles less than 400 nm to pass through. We have developed targeted nanodroplets that are less than 400 nm in size and are capable of encapsulating drug molecules which can be released at the tumor site upon insonation. These nanodroplets are targeted to the α 6β 1 receptor, which is upregulated in prostate cancer.

Original languageEnglish (US)
Title of host publicationAIP Conference Proceedings
Pages525-527
Number of pages3
Volume829
DOIs
StatePublished - May 8 2006
Externally publishedYes
EventTHERAPEUTIC ULTRASOUND: 5th International Symposium on Therapeutic Ultrasound - Boston, MA, United States
Duration: Oct 27 2005Oct 29 2005

Other

OtherTHERAPEUTIC ULTRASOUND: 5th International Symposium on Therapeutic Ultrasound
CountryUnited States
CityBoston, MA
Period10/27/0510/29/05

Fingerprint

therapy
tumors
encapsulating
vessels
drugs
cancer
molecules

Keywords

  • Nanodroplets
  • Paclitaxel
  • Perfluorocarbon
  • Targeted delivery

ASJC Scopus subject areas

  • Physics and Astronomy(all)

Cite this

Schumann, P., Labell, R., Penrose, K., Kerschen, A., Unger, E. C., Matsunaga, T. O., & Zutshi, R. (2006). Ultrasound-mediated therapies using receptor-targeted nanodroplets. In AIP Conference Proceedings (Vol. 829, pp. 525-527) https://doi.org/10.1063/1.2205529

Ultrasound-mediated therapies using receptor-targeted nanodroplets. / Schumann, P.; Labell, R.; Penrose, K.; Kerschen, A.; Unger, Evan C; Matsunaga, Terry O; Zutshi, R.

AIP Conference Proceedings. Vol. 829 2006. p. 525-527.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Schumann, P, Labell, R, Penrose, K, Kerschen, A, Unger, EC, Matsunaga, TO & Zutshi, R 2006, Ultrasound-mediated therapies using receptor-targeted nanodroplets. in AIP Conference Proceedings. vol. 829, pp. 525-527, THERAPEUTIC ULTRASOUND: 5th International Symposium on Therapeutic Ultrasound, Boston, MA, United States, 10/27/05. https://doi.org/10.1063/1.2205529
Schumann P, Labell R, Penrose K, Kerschen A, Unger EC, Matsunaga TO et al. Ultrasound-mediated therapies using receptor-targeted nanodroplets. In AIP Conference Proceedings. Vol. 829. 2006. p. 525-527 https://doi.org/10.1063/1.2205529
Schumann, P. ; Labell, R. ; Penrose, K. ; Kerschen, A. ; Unger, Evan C ; Matsunaga, Terry O ; Zutshi, R. / Ultrasound-mediated therapies using receptor-targeted nanodroplets. AIP Conference Proceedings. Vol. 829 2006. pp. 525-527
@inproceedings{0d74639648e0484d818c40cd5017f5bf,
title = "Ultrasound-mediated therapies using receptor-targeted nanodroplets",
abstract = "Angiogenic vessels at tumor sites are leaky and allow particles less than 400 nm to pass through. We have developed targeted nanodroplets that are less than 400 nm in size and are capable of encapsulating drug molecules which can be released at the tumor site upon insonation. These nanodroplets are targeted to the α 6β 1 receptor, which is upregulated in prostate cancer.",
keywords = "Nanodroplets, Paclitaxel, Perfluorocarbon, Targeted delivery",
author = "P. Schumann and R. Labell and K. Penrose and A. Kerschen and Unger, {Evan C} and Matsunaga, {Terry O} and R. Zutshi",
year = "2006",
month = "5",
day = "8",
doi = "10.1063/1.2205529",
language = "English (US)",
isbn = "073540321X",
volume = "829",
pages = "525--527",
booktitle = "AIP Conference Proceedings",

}

TY - GEN

T1 - Ultrasound-mediated therapies using receptor-targeted nanodroplets

AU - Schumann, P.

AU - Labell, R.

AU - Penrose, K.

AU - Kerschen, A.

AU - Unger, Evan C

AU - Matsunaga, Terry O

AU - Zutshi, R.

PY - 2006/5/8

Y1 - 2006/5/8

N2 - Angiogenic vessels at tumor sites are leaky and allow particles less than 400 nm to pass through. We have developed targeted nanodroplets that are less than 400 nm in size and are capable of encapsulating drug molecules which can be released at the tumor site upon insonation. These nanodroplets are targeted to the α 6β 1 receptor, which is upregulated in prostate cancer.

AB - Angiogenic vessels at tumor sites are leaky and allow particles less than 400 nm to pass through. We have developed targeted nanodroplets that are less than 400 nm in size and are capable of encapsulating drug molecules which can be released at the tumor site upon insonation. These nanodroplets are targeted to the α 6β 1 receptor, which is upregulated in prostate cancer.

KW - Nanodroplets

KW - Paclitaxel

KW - Perfluorocarbon

KW - Targeted delivery

UR - http://www.scopus.com/inward/record.url?scp=33845393830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845393830&partnerID=8YFLogxK

U2 - 10.1063/1.2205529

DO - 10.1063/1.2205529

M3 - Conference contribution

AN - SCOPUS:33845393830

SN - 073540321X

SN - 9780735403215

VL - 829

SP - 525

EP - 527

BT - AIP Conference Proceedings

ER -